MN55 (apple)

From WikiMD's Medical Encyclopedia

Cultivar of apple



MN55 (Apple)[edit]

MN55, also known as Rave, apple cultivar

The MN55, commercially known as Rave, is a cultivar of apple developed by the University of Minnesota. It is a hybrid of the Honeycrisp and MonArk apple varieties. The MN55 is notable for its early ripening, crisp texture, and unique flavor profile.

Development[edit]

The MN55 apple was developed by the University of Minnesota's apple breeding program, which is renowned for creating the popular Honeycrisp apple. The breeding program aimed to produce an apple that ripens earlier than the Honeycrisp while maintaining its desirable qualities such as crispness and juiciness. The MN55 was achieved by cross-pollinating the Honeycrisp with the MonArk apple, a variety known for its early ripening.

Characteristics[edit]

The MN55 apple is characterized by its vibrant red and yellow skin, which is visually appealing. It has a crisp and juicy texture, similar to its Honeycrisp parent, but with a distinct flavor that is both sweet and slightly tart. The apple is known for its early harvest time, typically ripening in late summer, which is earlier than many other apple varieties.

Commercialization[edit]

The MN55 apple is marketed under the brand name "Rave" by Stemilt Growers, a major fruit company in the United States. The commercialization of the MN55 began in 2017, and it has since gained popularity for its unique taste and early availability in the apple market.

Cultivation[edit]

MN55 apples are primarily grown in the United States, with significant production in the state of Washington. The apple trees are known for their hardiness and ability to thrive in various climates, making them suitable for cultivation in different regions.

Related Pages[edit]

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.